Cytosorbents corp (CTSO)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Cash flows from operating activities:
Net loss

-3,452

-3,949

-6,885

-3,547

-4,883

-5,403

-3,004

-5,821

-2,982

-3,147

-2,054

-1,734

-1,524

-4,906

-2,015

-3,005

-1,836

-3,346

-2,847

1,434

-4,716

-4,994

-1,498

-1,853

-975

-669

-964

-1,414

-1,628

-537

-651

-1,047

-1,426

Adjustments to reconcile net loss to net cash used by operating activities:
Contributed technology expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Consulting expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Management unit expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Expense for issuance of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Expense for issuance of options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

33

40

225

46

12

4

0

Amortization of deferred compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Common stock issued as inducement to convert convertible notes payable and accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Non-cash compensation

477

166

634

110

261

213

153

363

217

-

-

-

-

-

-

-

-

-

-

-

-

0

90

0

90

0

0

65

0

0

0

0

0

Depreciation and amortization

181

167

138

137

138

133

139

60

56

56

58

40

63

52

39

37

32

34

34

23

21

-4

24

26

19

16

15

17

14

22

10

10

10

Amortization of debt costs

35

-

31

23

23

-

23

23

25

-

25

15

15

-

15

0

0

-

-

-

-

0

35

80

82

82

47

2

178

50

38

38

344

Gain on disposal of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Gain on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Interest expense paid with Series B Preferred Stock in connection with conversion of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Abandoned patents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

Bad debt

7

116

0

-58

14

-1

7

5

4

-2

0

2

1

65

0

0

0

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Stock-based compensation

729

491

802

144

227

1,573

273

2,065

524

1,462

960

798

92

2,032

124

492

107

122

113

82

63

545

45

47

57

-

-

-

-

-

-

-

-

Change in warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

190

-18

-

771

-3,596

2,007

2,326

-234

342

-316

0

0

0

0

-

-

-

-

Foreign currency transaction loss

-668

701

-955

297

-393

-240

-108

-793

358

232

348

719

153

-534

73

-128

231

-174

73

163

-448

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Grants and accounts receivable

1,023

1,050

117

85

-611

329

749

651

117

-154

268

250

284

142

454

197

95

105

47

-179

-104

299

234

3

-125

259

109

-30

62

-0

8

3

3

Inventories

-134

320

292

275

395

71

-4

105

-114

-285

189

18

20

-197

6

99

-249

-98

273

355

140

167

83

157

-99

-116

-114

-78

-127

56

90

66

37

Prepaid expenses and other current assets

-87

910

225

253

-435

521

226

21

-38

68

-47

-75

131

108

57

-32

-320

143

94

126

-543

488

-139

171

-412

447

1

61

-381

359

-29

99

3

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

7

0

-0

4

0

16

0

-18

9

-8

-0

0

0

Accounts payable and accrued expenses

-1,055

1,830

-250

908

-1,064

1,435

633

-636

272

617

-665

-77

-42

769

151

499

211

123

153

-76

-283

606

-213

345

-240

79

-123

198

-36

63

23

17

43

Accrued interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-0

-2

-2

-111

-154

-163

435

0

0

-

-

-

-

Net cash used by operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,922

-1,261

-

-2,263

-2,598

-1,960

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used by operating activities

-3,209

-4,124

-5,208

-3,188

-4,237

-2,707

-2,635

-3,293

-2,203

-409

-2,183

-1,883

-1,984

-

-

-

-

-

-

-

-

-

-

-1,460

-800

-1,102

-553

-1,023

-809

-761

-635

-1,146

-1,072

Cash flows from investing activities:
Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Purchases of property and equipment

235

140

126

138

292

176

26

225

242

410

350

158

70

-14

57

62

35

107

103

88

104

63

34

33

21

5

10

20

2

19

-1

1

0

Payments for patent costs

273

262

188

188

181

146

249

222

229

171

188

193

133

113

129

141

71

111

82

9

36

124

28

57

4

158

6

12

0

-2

-4

13

11

Proceeds from sale of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,494

1,494

1,196

1,246

4,745

0

0

0

-

-

0

0

0

0

0

0

Purchases of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

298

1,743

249

1,445

2,241

-657

2,601

0

4,745

0

0

0

0

0

0

0

0

Loan receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Net cash used by investing activities

-508

-403

-315

-327

-474

-323

-276

-448

-472

-581

-539

-352

-204

-

-

-

-

-

-

-

-

-

-

-90

-4,770

-164

-16

-33

-2

-17

5

-14

-11

Cash flows from financing activities:
Net cash used by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,037

-404

-

1,058

-346

-1,134

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from long-term debt

-

-

-

-

-

0

0

0

666

0

0

5,000

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of long-term debt

-

-

-

-

-

0

0

0

666

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of debt acquisition costs

-

-

-

-

-

-

-

0

147

-

0

1

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of preferred stock, net of related issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Equity contributions - net of fees incurred

17,743

673

0

0

0

209

2,013

5,856

6,046

1,904

1,454

10,320

0

-

-

-

-

115

0

0

9,408

-

-

-

9,751

600

700

449

450

450

950

1,099

1,000

Proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Proceeds from borrowing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

580

165

1,098

0

0

0

0

700

Proceeds from subscription receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Proceeds from exercise of stock options

138

11

312

180

236

266

507

904

529

410

149

30

1

38

76

-21

25

47

113

239

10

18

29

9

51

0

5

15

0

10

0

0

0

Proceeds from exercise of warrants

0

0

0

0

1,768

-0

47

1,218

15

592

85

0

175

15

25

22

2

433

454

225

593

156

0

0

0

0

139

0

0

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,882

27

-

567

464

10,011

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

17,881

772

5,220

180

2,004

475

2,568

7,979

6,442

2,907

1,689

15,349

176

-

-

-

-

-

-

-

-

-

-

9

9,803

1,180

1,009

1,563

450

460

950

1,099

1,700

Effect of exchange rates on cash

-7

9

-60

30

-14

12

-27

-45

0

5

31

48

7

-5

9

136

-141

28

4

79

-103

-125

118

4

0

-80

40

-0

-2

-12

0

0

0

Net change in cash and cash equivalents

14,156

-3,745

-363

-3,305

-2,721

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash and cash equivalents

-

-

-

-

-

-

-

-

3,767

-

-1,001

13,162

-2,005

-1,129

-2,295

5,132

-1,779

-2,068

-631

-2,401

6,813

3,171

-4,445

-1,537

4,233

-166

479

505

-364

-331

319

-61

616

Supplemental disclosure of cash flow information:
Cash paid during the period for interest

318

327

273

231

227

223

263

142

261

227

191

111

104

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid during the period for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

0

-

0

0

0

-

-

0

0

0

0

0

0

0

0

0

0

Supplemental disclosure of non-cash financing activities
Fair value of warrant liability upon issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

862

-

-

-

-

-

-

-

-

Fair value of warrant liability upon issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

Debt discount in connection with issuance of convertible debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

142

188

0

-0

0

0

87

Settlement of accrued bonuses with restricted stock units

328

0

0

0

425

0

0

164

380

0

0

63

144

0

0

0

0

-

-

-

-

0

0

0

7

15

23

0

10

10

22

25

188

Equity contribution proceeds in transit

1,798

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Note payable principal and interest conversion to equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,226

-685

290

-0

395

Issuance of management units in settlement of cost of raising capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Change in fair value of management units for cost of raising capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Issuance of common stock in exchange for stock subscribed

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Costs paid from proceeds in conjunction with issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

115

0

0

903

0

0

0

748

0

0

0

0

0

0

0

0

Preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,496

1,281

1,374

1,114

667

525

616

586

640

629

577

663

Net effect of conversion of common stock to preferred stock prior to merger

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0